Responding population of dogs treated with ABT-510
| Breed | Tumor histology | TNM stage | Response | Response duration (d) |
|---|---|---|---|---|
| Golden retriever | NHL | IVa | CR | 240 |
| Doberman | Oral fibrosarcoma | T2N0M0 | PR | 970 |
| Norfolk terrier | Oral fibrosarcoma | T2N0M0 | CR | >450 |
| Standard poodle | Hemangiosarcoma | T(sx)N0M1 | PR | 530 |
| Golden retriever | Lingual/labial hemangiosarcoma | T2N0M1 | PR | 570 |
| Labrador retriever | Cutaneous T-cell lymphoma | Cutaneous | PR | 75 |
| Dalmatian | Hemangiopericytoma | T2N0M0 | CR | >450 |
| Labrador retriever mix | NHL | IIIa | PR | >150 |
| Labrador retriever mix | Multicentric cutaneous plasmacytomas | T2N0M1 | PR | >120 |
| Labrador retriever mix | Cutaneous B-cell lymphoma | Cutaneous | SD | 140 |
| Shepherd mix | Metastatic insulinoma | T(sx)N0M1 | SD | 240 |
| Scottish terrier | Thyroid adenocarcinoma | T2N0M0 | SD | 150 |
| Dachshund | NHL | IIIa | SD | 62 |
| Labrador retriever mix | Transitional cell carcinoma | T2N0M0 | SD | 420 |
| Shetland sheepdog | Fibrosarcoma | T(sx)N0M1 | SD | 453 |
| Springer spaniel | Papillary carcinoma, nasal | T3bN0M0 | SD | 120 |
| Labrador retriever mix | Cutaneous plasmacytoma | T2N0M1 | SD | 90 |
| Maltese | Transitional cell carcinoma | T2N0M0 | SD | 270 |
| Shepherd mix | Thyroid adenocarcinoma | T3N0M0 | SD | >210 |
| Shepherd mix | Thyroid carcinoma | T2bN0M0 | SD | >270 |
| Australian cattle dog mix | Rhabdomyosarcoma | T3N0M0 | SD | >120 |
| Puli | Anaplastic transitional cell carcinoma | T2N0M0 | SD | >90 |
| Fox terrier | Prostatic adenocarcinoma | T2N0M0 | SD | >120 |